Budesonide/formoterol therapy: effective and appropriate use in asthma and chronic obstructive pulmonary disease
| Autor: | Jill Davis, Douglas W. Mapel, Melissa H. Roberts |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Budesonide
medicine.medical_specialty Exacerbation 03 medical and health sciences Pulmonary Disease Chronic Obstructive 0302 clinical medicine Internal medicine Formoterol Fumarate medicine Humans 030212 general & internal medicine Asthma Fluticasone Randomized Controlled Trials as Topic Retrospective Studies business.industry Health Policy Inhaler medicine.disease Fluticasone-Salmeterol Drug Combination Bronchodilator Agents Drug Combinations 030228 respiratory system Budesonide/formoterol Formoterol Salmeterol business medicine.drug |
| Zdroj: | Journal of comparative effectiveness research. 9(4) |
| ISSN: | 2042-6313 |
| Popis: | Aim: Quality, real-world comparative effectiveness (CE) studies of asthma and chronic obstructive pulmonary disease therapy efficacy are scarce. We identified and evaluated peer-reviewed CE and appropriate-use evaluations of budesonide/formoterol combination (BFC) maintenance therapy. Materials & methods: Analyses were limited to retrospective, real-world utilization studies of BFC delivered by pressurized metered-dose inhalers. Results: In a CE study of BFC versus fluticasone/salmeterol combinations (FSC) in asthma, BFC users had fewer total exacerbations. In appropriate-use studies of asthma treatment, BFC patients were consistently more likely to meet treatment escalation recommendations. BFC comparisons with FSC or tiotropium for chronic obstructive pulmonary disease found differences in exacerbation rates and rescue inhaler use. Conclusion: We found available, good quality BFC CE and appropriate-use articles; however, all had limitations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|